DEVICE WARNING LETTER DECLINE CONTINUES UNDER PILOT PROGRAM
This article was originally published in The Silver Sheet
FDA MEDICAL DEVICE INSPECTION INITIATIVES continue to foster greater interaction between manufacturers and the agency. The agency's warning letter pilot and "customer satisfaction" survey program are encouraging post-inspectional dialogue while the recently launched QSIT device auditing approach provides for increased pre-inspection communications. As both device center and field personnel face additional duties due to recent device premarket initiatives, FDA's Office of Regional Operations is exploring ways to enhance its productivity and streamline its processes, including adoption of a "quality management system" WARNING LETTERS: QS reg violations at Alaris Medical require quarterly certifications of corrective actions by an outside consultant; Synthes cited for inadequate corrective action and final acceptance procedures
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.